Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -38.32% is 31% above its 5-year average of -55.40%, near the low end of its 5-year range (-132.33%–2267.23%).
109.05% below its 12-month average of 423.64%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -36.90%.
EBITDA MARGIN
-38.32%
EBITDA MARGIN AVG TTM
423.64%
EBITDA MARGIN AVG 3Y
-58.15%
EBITDA MARGIN AVG 5Y
-55.40%
EBITDA MARGIN AVG 10Y
-32.01%
EBITDA MARGIN AVG 15Y
-36.80%
EBITDA MARGIN AVG 20Y
-33.97%
CURRENT VS TTM AVG
-109.05%
CURRENT VS 3Y AVG
+34.11%
CURRENT VS 5Y AVG
+30.84%
CURRENT VS 10Y AVG
-19.70%
CURRENT VS 15Y AVG
-4.12%
CURRENT VS 20Y AVG
-12.80%
Ionis Pharmaceuticals, Inc.
Market Cap
$7.29B
EBITDA Margin
-38.32%
TTM Avg
423.64%
3Y Avg
-58.15%
5Y Avg
-55.40%
Market Cap
$7.57B
EBITDA Margin
-92.07%
TTM Avg
-49.82%
3Y Avg
-47.83%
5Y Avg
-47.83%
Market Cap
$7.58B
EBITDA Margin
-684.44%
TTM Avg
-1767.79%
3Y Avg
-2575.30%
5Y Avg
-1786.18%
Market Cap
$7.60B
EBITDA Margin
36.33%
TTM Avg
34.52%
3Y Avg
30.06%
5Y Avg
28.41%
Market Cap
$7.66B
EBITDA Margin
-2336.10%
TTM Avg
-3741.43%
3Y Avg
-3741.43%
5Y Avg
-3741.43%
Market Cap
$7.75B
EBITDA Margin
8.34%
TTM Avg
-21.08%
3Y Avg
-58.51%
5Y Avg
-29.82%
Market Cap
$6.65B
EBITDA Margin
15.93%
TTM Avg
16.80%
3Y Avg
17.55%
5Y Avg
18.41%
Market Cap
$8.00B
EBITDA Margin
20.05%
TTM Avg
16.44%
3Y Avg
-1944.65%
5Y Avg
-32112.59%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ionis Pharmaceuticals, Inc. (IONS) | $7.29B | -38.32% | 423.64% | -58.15% | -55.40% |
| Hinge Health, Inc. (HNGE)vs › | $7.57B | -92.07% | -49.82% | -47.83% | -47.83% |
| Cytokinetics, Incorporated (CYTK)vs › | $7.58B | -684.44% | -1767.79% | -2575.30% | -1786.18% |
| HealthEquity, Inc. (HQY)vs › | $7.60B | 36.33% | 34.52% | 30.06% | 28.41% |
| Alkermes plc (ALKS)vs › | $6.97B | 19.05% | 23.95% | 20.94% | 15.97% |
| Praxis Precision Medicines, Inc. (PRAX)vs › | $7.66B | -2336.10% | -3741.43% | -3741.43% | -3741.43% |
| Caris Life Sciences, Inc. (CAI)vs › | $7.75B | 8.34% | -21.08% | -58.51% | -29.82% |
| Chemed Corporation (CHE)vs › | $6.65B | 15.93% | 16.80% | 17.55% | 18.41% |
| TG Therapeutics, Inc. (TGTX)vs › | $8.00B | 20.05% | 16.44% | -1944.65% | -32112.59% |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.52B | 6.82% | 6.08% | -0.44% | -8.67% |
Gross Margin
98.2%
EBITDA Margin
-38.3%
Operating Margin
-40.5%
Net Margin
-64.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -36.90% |
| 2026-03-31 | -44.96% |
| 2025-12-31 | 2267.23% |
| 2025-09-30 | -99.34% |
| 2025-06-30 | 32.14% |
| 2025-03-31 | -107.48% |
| 2024-12-31 | -46.59% |
| 2024-09-30 | -106.99% |
| 2024-06-30 | -26.86% |
| 2024-03-31 | -120.39% |
| 2023-12-31 | -0.16% |
| 2023-09-30 | -95.47% |
| 2023-06-30 | -44.85% |
| 2023-03-31 | -83.16% |
| 2022-12-31 | -132.33% |
| 2022-09-30 | -33.84% |
| 2022-06-30 | -60.11% |
| 2022-03-31 | -37.07% |
| 2021-12-31 | 51.27% |
| 2021-09-30 | -60.97% |
| 2021-06-30 | -54.04% |
| 2021-03-31 | -78.06% |
| 2020-12-31 | -6.24% |
| 2020-09-30 | -20.04% |
| 2020-06-30 | -32.79% |
| 2020-03-31 | -42.75% |
| 2019-12-31 | 53.62% |
| 2019-09-30 | 3.70% |
| 2019-06-30 | -8.92% |
| 2019-03-31 | 42.24% |
| 2018-12-31 | 7.45% |
| 2018-09-30 | -10.54% |
| 2018-06-30 | -40.20% |
| 2018-03-31 | -0.34% |
| 2017-12-31 | -0.41% |
| 2017-09-30 | 11.73% |
| 2017-06-30 | 7.90% |
| 2017-03-31 | 18.88% |
| 2016-12-31 | 27.08% |
| 2016-09-30 | 16.57% |
| 2016-06-30 | -121.28% |
| 2016-03-31 | -142.20% |
| 2015-12-31 | -116.95% |
| 2015-09-30 | -92.67% |
| 2015-06-30 | 39.26% |
| 2015-03-31 | -11.15% |
| 2014-12-31 | 14.66% |
| 2014-09-30 | -43.29% |
| 2014-06-30 | -7.57% |
| 2014-03-31 | -97.20% |
| 2013-12-31 | -18.21% |
| 2013-09-30 | -97.94% |
| 2013-06-30 | -14.38% |
| 2013-03-31 | 9.65% |
| 2012-12-31 | -74.73% |
| 2012-09-30 | -229.93% |
| 2012-06-30 | 10.93% |
| 2012-03-31 | -79.43% |
| 2011-12-31 | -20.41% |
| 2011-09-30 | -98.70% |
| 2011-06-30 | -50.57% |
| 2011-03-31 | -76.17% |
| 2010-12-31 | -22.49% |
| 2010-09-30 | -24.72% |
| 2010-06-30 | -73.04% |
| 2010-03-31 | -16.31% |
| 2009-12-31 | -17.70% |
| 2009-09-30 | -33.79% |
| 2009-06-30 | -7.80% |
| 2009-03-31 | -2.03% |
| 2008-12-31 | 29.50% |
| 2008-09-30 | 4.65% |
| 2008-06-30 | 7.63% |
| 2008-03-31 | -33.96% |
| 2007-12-31 | -26.48% |
| 2007-09-30 | 29.12% |
| 2007-06-30 | -484.50% |
| 2007-03-31 | -853.10% |
| 2006-12-31 | -112.92% |
| 2006-09-30 | -521.12% |
| 2006-06-30 | -362.38% |
| 2006-03-31 | -323.03% |
| 2005-12-31 | -19.06% |
| 2005-09-30 | -145.87% |
| 2005-06-30 | -107.97% |
| 2005-03-31 | -315.87% |
| 2004-12-31 | -379.86% |
| 2004-09-30 | -246.12% |
| 2004-06-30 | -216.80% |
| 2004-03-31 | -181.54% |
| 2003-12-31 | -221.47% |
| 2003-09-30 | -168.82% |
| 2003-06-30 | -129.99% |
| 2003-03-31 | -135.28% |
| 2002-12-31 | -4.31% |
| 2002-09-30 | -86.25% |
